Whether the reversible cardiac myosin inhibitor aficamten can improve peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy is unknown.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: [ Ссылка ]
#cardiology #clinicaltrials #nejm
